Bolt Biotherapeutics CSO David Dornan resigns, stays as consultant for 6 months

Bolt Biotherapeutics, Inc.

David Dornan, Ph.D. resigned as Chief Scientific Officer effective March 11, 2022.
Entered consulting agreement for 6 months at $500/hour to assist transition.
Outstanding equity awards will continue to vest during consulting period.
Consultant reports to CEO Randall Schatzman.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

David Dornan

Chief Scientific Officer

BOLT · Bolt Biotherapeutics, Inc.

Effective: 2022-03-11
Filed: March 4, 2022, 6:59 PM ET

On March 1, 2022, David Dornan, Ph.D. notified Bolt Biotherapeutics, Inc. of his resignation as our Chief Scientific Officer, effective March 11, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David Dornan resigned as Chief Scientific Officer at Bolt Biotherapeutics, Inc..

Action: resigned
Role: Chief Scientific Officer

Exact text from the filing

On March 1, 2022, David Dornan, Ph.D. notified Bolt Biotherapeutics, Inc. of his resignation as our Chief Scientific Officer, effective March 11, 2022.

View on SEC.gov

Bolt Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-002873

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.